DUBLIN--(BUSINESS WIRE)--The "World Hemophilia Treatment Market - Opportunities and Forecasts, 2014 - 2022" report has been added to Research and Markets' offering.
This report gives a pin-point analysis of market dynamics. It analyzes the limitations in this market and also describes the growth opportunities.
In this report estimations are made by considering present market conditions and future market potential for the period 2014-2020.
The market for treatment of hemophilia is segmented based on the medicines used to give understanding about current scenario of available drugs and to understand the need for novel therapies.
Hemophilia is a hereditary genetic disorder which impairs body's ability to control coagulation or blood clotting. In this disease, clotting factors control bleeding from a broken vessel is deficient; therefore, coagulation does not occur. Of the two types of hemophilia, hemophilia A has higher prevalence compared to the other variant hemophilia B.
Acquired hemophilia is a rare non genetic form of hemophilia in which autoantibodies develop against the plasma coagulation factor. The development of novel coagulating factors and technological advancements are driving the growth of this market. Lack of available medicines, awareness of this disease and high cost of treatment are the major restraining factors in this market.
The advancements in gene therapy and approaching approval of drugs for treatment of hemophilia provide growth opportunities in this market.
The report analyzes global hemophilia treatment market using Porter's five forces model. Porter's model explains the constitution of industry and helps in analyzing the bargaining power of buyers and suppliers. In this market, high initial capital investment may be a threat for new entrants.
- Baxter International Inc.
- Bayer AG
- Biogen Idec, Inc.
- Pfizer Inc.
- Swedish Orphan Biovitrum AB
For more information about this report visit https://www.researchandmarkets.com/research/q94xrt/world_hemophilia?w=4